Rivaroxaban FDA Approved Indications:
- Nonvalvular Atrial Fibrillation: 15 or 20 mg, once daily with food
- Treatment of DVT and/or PE: 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally
once daily with food for the remaining treatment
- Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE: 10 mg
once daily with or without food, after at least 6 months of standard anticoagulant treatment
- Prophylaxis of DVT Following Hip or Knee Replacement Surgery: 10 mg orally once daily with or without food
- Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk
of Bleeding: 10 mg once daily, with or without food, in hospital and after hospital discharge for a total
recommended duration of 31 to 39 days
Mode of action
Vaxato is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.
Indications and Dosage Administration
Package and Storage
Vaxato® 10mg
10 tablet
Store below 30°C in a dry place
Vaxato® 15mg
30 tablet
Store below 30°C in a dry place
Vaxato® 20mg
30 tablet
Store below 30°C in a dry place
All Rights Reserved Liptis Pharmaceuticals 2021